Sunny Pharmtech held its annual shareholders’ meeting on the 16th, where Chairman Yon Lian Wu announced the company’s commitment to focusing on the development of high-barrier pharmaceuticals and accelerating its “one drug, multiple approvals” strategy to penetrate international markets. The company also plans to enhance its competitiveness by optimizing production lines to reduce manufacturing costs.
Benefiting from continued growth in shipments of its anti-infective drug (NFT-C) and anticancer injectable (CPA-I), Sunny Pharmtech saw stable growth in drug sales and profit-sharing revenues, driving a 30% year-on-year increase in 2024 and reaching consolidated revenue of NT$418 million. However, due to a decline in one-time milestone payments and CDMO (contract development and manufacturing organization) revenue compared to the same period last year, the proportion of high-margin milestone income fell to 7%. Meanwhile, increased investment in high-barrier drug R&D through newly signed development contracts pushed operating expenses up by 8.8%, resulting in an annual net loss of NT$1.05 per share.
Wu expressed optimism about the company’s future growth prospects. A generic drug for multiple sclerosis is expected to receive approval by the end of this year, potentially tapping into the US$640 million U.S. market. Additionally, a drug for pulmonary fibrosis is scheduled for FDA submission later this year. Developed jointly with a domestic partner, this drug targets a market where the original brand generated US$2.4 billion in U.S. sales last year.
Emphasizing the continuation of its multi-approval strategy, Wu noted that, in addition to submitting a marketing authorization application in the UK for its anti-infective drug last year, Sunny Pharmtech also secured regulatory approval in May for Carprost Aminobutramine Injection in China. The company has recently filed for drug approvals in the Middle East and Malaysia and is actively exploring business collaborations in other regions to maximize product value and broaden its reach beyond the U.S. market.
In its CDMO operations, the company has completed over 40 projects to date, serving both domestic and international pharmaceutical companies. In 2024, Sunny Pharmtech signed a manufacturing contract with a well-known international pharmaceutical firm for a prostate cancer drug targeting the U.S. market. The company is also in talks with multinational drug manufacturers regarding global contract manufacturing of high-potency injectable products, with CDMO operations expected to contribute increasingly to future growth.
Looking ahead to 2025, Wu stated that in response to global challenges such as U.S. tariff policies, supply chain localization, and market competition, Sunny Pharmtech will continue leveraging its five key competitive strengths: capabilities spanning from API development to finished product manufacturing, expertise in high-potency drug development, regulatory experience in filing generics in the U.S., FDA and TFDA-certified facilities, and diverse, high-barrier dosage form technologies. The company will maintain its focus on high-tech, niche markets, continue R&D efforts, expand its multi-approval strategy, and enhance cost-efficiency through production line optimization to strengthen its overall competitiveness.
Resource: 祥翊加速一藥多證布局 拚進國際市場
